Booster Dose of sIPV Co-administered With MMR and HepA-I.

Summary

This is an Open-labeled, Randomized, Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of Booster Dose of Sabin Strain Inactivated Poliovirus Vaccine (Vero cell) (sIPV) Co-administered with Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine and Inactivated Hepatitis A (Hep-A) Vaccine.

Timeline

Start

2024-08-08

Primary completion

2025-09-10

Completion

2025-10-10

Outcome

Met primary endpoint

paper all pairwise SCR differences met non-inferiority (-10% margin). PMID 41295459 ↗

paper CONCLUSIONS: Same-day sIPV co-administration with MMRV or HepA was non-inferior and well tolerated, supporting programmatic adoption. PMID 41295459 ↗

Publications

• Hu J, Han W, Chu K, Zhang H, Tuo L, Duan X, Li J, Yuan F, Luan C, Pan H, Jiao P. Immunogenicity and Safety of Sabin Strain Inactivated Poliovirus Vaccine Booster Dose Administered Separately or Concomitantly with Inactivated Hepatitis A Vaccine or Measles-Mumps-Rubella Combined Attenuated Live Vaccine: An Open-Labelled, Randomized, Controlled, Phase 4 Clinical Trial. Vaccines (Basel). 2025 Oct 23;13(11):1087. doi: 10.3390/vaccines13111087.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HepA-I	Vaccine	—	—
Subject	Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine	Vaccine	—	—
Subject	Sabin Strain Inactivated Poliovirus Vaccine (Vero cell)	Vaccine	—	—

Indications